Adding obinutuzumab to ibrutinib enhances depletion of CLL cells in peripheral blood and bone marrow after 1 & 6 months combined therapy initial results from the Bloodwise TAP IciCLLe extension study.
Authors
Rawstron, AMunir, T
Munoz-Vicente, S
Brock, K
Yates, F
Bishop, R
Dalal, S
de Tute, R
Sheehy, O
Pettitt, A
Foz, C
Fegan, C
Devereux, S
MacDonald, D
Bloor, Adrian
Hillman, P
Affiliation
St. James's Institute of Oncology, LeedsIssue Date
2017